Journey Medical: Q2 Report Confirms Thesis On Track As Emrosi Launch Gains Traction
· seekingalpha.com
Journey Medical Emrosi growth drives a 23% Q2 revenue jump and positive EBITDA. Click for more on DERM stock.
Analyst’s Disclosure: I/we have a beneficial long position in the shares of DERM either through stock ownership, options, or other derivatives. I wrote this a...